A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration
In many countries, a second dose of a combined measles, mumps, and rubella (MMR) vaccine is recommended at 4–6 years of age – similarly to the booster of diphtheria, tetanus, acellular pertussis, and inactivated polio vaccine (DTaP-IPV) and the second dose of varicella vaccine (VV). Vaccine co-admin...
| Published in: | Human Vaccines & Immunotherapeutics |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-04-01
|
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2018.1554971 |